KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Discontinued Operations (2022 - 2025)

TherapeuticsMD's Cash from Discontinued Operations history spans 5 years, with the latest figure at 7000.0 for Q4 2025.

  • For Q4 2025, Cash from Discontinued Operations fell 40.0% year-over-year to 7000.0; the TTM value through Dec 2025 reached 30000.0, up 93.15%, while the annual FY2025 figure was 30000.0, 93.15% up from the prior year.
  • Cash from Discontinued Operations reached 7000.0 in Q4 2025 per TXMD's latest filing, down from 47000.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 136529000.0 in Q2 2022 to a low of 131010000.0 in Q4 2022.
  • Average Cash from Discontinued Operations over 4 years is 2435312.5, with a median of 85500.0 recorded in 2024.
  • Peak YoY movement for Cash from Discontinued Operations: crashed 226.9% in 2024, then soared 141.23% in 2025.
  • A 4-year view of Cash from Discontinued Operations shows it stood at 131010000.0 in 2022, then soared by 97.8% to 2881000.0 in 2023, then surged by 99.83% to 5000.0 in 2024, then tumbled by 40.0% to 7000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Cash from Discontinued Operations are 7000.0 (Q4 2025), 47000.0 (Q3 2025), and 57000.0 (Q2 2025).